Why Quest Diagnostics ( DGX ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing
DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Addus HomeCare and The Pennant
Quest Diagnostics, DaVita, Addus HomeCare, and The Pennant Group are positioned to benefit from telehealth, AI adoption, and rising demand in the $747B home healthcare market.
4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.
Here's Why Quest Diagnostics ( DGX ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration - Quest Diagnostics ( NYSE:DGX )
SECAUCUS, N.J., Sept. 23, 2025 /PRNewswire/ -- Quest Diagnostics DGX and Epic today announced a first-of-its-kind collaboration designed to streamline and improve experiences for healthcare providers and patients that engage Quest for laboratory testing in the United States.
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?
DGX posts strong gains from physician and hospital channels while advancing AI-powered solutions.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Payscale Acquires AI-Powered Recruiting Platform Datapeople, Creating Alignment Between Talent Acquisition and Compensation
BOSTON, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Payscale Inc., the leading provider of compensation intelligence solutions, announced today that it has acquired Datapeople, an AI-powered recruiting platform that helps hiring teams create clearer, more effective, and more compliant job postings.
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
Should You Continue to Hold EXAS Stock in Your Portfolio?
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
Quest Diagnostics: A Solid Investment or a Risky Bet?
Join us as we analyze Quest Diagnostics and uncover whether this lab giant is a smart investment choice for the future. With insights from industry experts, you won't want to miss this evaluation!
Encompass Health ( EHC ) Up 8.6% Since Last Earnings Report: Can It Continue?
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Quest Diagnostics ( DGX ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Is Chemed ( CHE ) Up 9.3% Since Last Earnings Report?
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics ( DGX ) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DGX Stock Gains Following a New Joint Venture With Corewell Health
Quest Diagnostics shares rise after forming a joint venture with Corewell Health to expand advanced lab services across Michigan.
This Quest Diagnostics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Quest Diagnostics ( NYSE:DGX ) , American Eagle Outfitters ( NYSE:AEO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. DA Davidson analyst Matt Summerville downgraded Symbotic Inc.
Why Is Quest Diagnostics ( DGX ) Up 8.2% Since Last Earnings Report?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Quest Diagnostics Stock Be in Your Portfolio Right Now?
DGX drives growth with advanced diagnostics, acquisitions and cost savings, but rising debt and macro risks weigh on its outlook.
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
HOLX's Genius digital cytology system and global rollout position its Cytology unit for long-term growth despite near-term headwinds.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MedWellAi, Inc Joins Trump Mobile In Engaging BrighterMD To Develop Ai-Inhanced Healthcare Telemedicine Platform, Focused On $24.46 Billion Corporate Wellness Market - MedWellAI ( OTC:MWAI )
CLEARWATER, Fla., Aug. 18, 2025 /PRNewswire/ -- MedWell Ai, Inc, ( "Company" ) MWAI is pleased to confirm the collaboration and execution of Software Development Agreement with BrighterMD, to develop and launch Company's latest initiative: TeleMD.Ai - Nationwide B2B and B2C Healthcare and ...
Here's Why Quest Diagnostics ( DGX ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Does the Market Think About Quest Diagnostics? - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics's DGX short percent of float has risen 3.64% since its last report. The company recently reported that it has 4.74 million shares sold short, which is 4.84% of all regular shares that are available for trading.
OraSure Appoints Anne Messing as Chief Commercial Officer
BETHLEHEM, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- OraSure Technologies, Inc. ( "OTI" ) ( NASDAQ: OSUR ) , a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
OraSure Appoints Anne Messing as Chief Commercial Officer - OraSure Technologies ( NASDAQ:OSUR )
BETHLEHEM, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- OraSure Technologies, Inc. ( "OTI" ) OSUR, a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
Healthcare Analytical Testing Services Market is expected to generate a revenue of USD 9.56 Billion by 2031, Globally, at 11.20% CAGR: Verified Market Research®
Lewes, Delaware, July 31, 2025 ( GLOBE NEWSWIRE ) -- The Global Healthcare Analytical Testing Services Market Size is projected to grow at a CAGR of 11.20% from 2024 to 2031, according to a new report published by Verified Market Research®.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Quest Diagnostics ( DGX ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
C3.ai Expands Beyond Oil: Is Diversification Paying Off?
AI's 48% surge in non-oil revenue and major wins in 19 industries show its diversification strategy gaining real ground.
Quest Diagnostics Raises 2025 Guidance
Diagnostic testing and information services provider Quest Diagnostics ( NYSE:DGX ) reported fiscal 2025 second-quarter results on Tuesday, July 22, that topped analysts' consensus expectations. Q2 revenue hit $2.76 billion and adjusted earnings per share ( EPS ) came in at $2.62.
Looking Into Quest Diagnostics's Recent Short Interest - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics's DGX short percent of float has risen 36.83% since its last report. The company recently reported that it has 4.98 million shares sold short, which is 5.09% of all regular shares that are available for trading.
Quest Diagnostics Boosts Its 2025 Outlook
Quest Diagnostics ( NYSE:DGX ) reported its second-quarter 2025 results on July 22, achieving consolidated revenue of $2.76 billion ( up 15.2% year over year ) , organic revenue growth of 5.2%, while adjusted EPS rose 11.5% year over year to $2.62.
Quest Diagnostics Q2 Earnings - Quest Diagnostics ( NYSE:DGX )
Q1 revenue rose 15.2% Y/Y to $2.76B, beating the $2.73B estimate; EPS of $2.62 topped the $2.58 consensus. Quest raised 2025 revenue forecast to $10.80 billion-$10.92 billion and EPS to $9.63-$9.83, above prior guidance and consensus.
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Quest ( DGX ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Tuesday, July 22, 2025 at 8:30 a.m. ETChairman, Chief Executive Officer, and President - Jim DavisContinue reading ...
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Quest Diagnostics ( DGX ) Beats Q2 Earnings and Revenue Estimates
Quest Diagnostics (DGX) delivered earnings and revenue surprises of +1.95% and +1.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics DGX has outperformed the market over the past 5 years by 493.73% on an annualized basis producing an average annual return of 508.21%. Currently, Quest Diagnostics has a market capitalization of $18.63 billion.
Should You Buy Quest Diagnostics Ahead of Earnings?
DGX is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.
Will Quest Diagnostics ( DGX ) Beat Estimates Again in Its Next Earnings Report?
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics ( DGX ) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Paysafe and Champion Homes have been highlighted as Zacks Bull and Bear of the Day
PSFE earns Bull of the Day with deep value and rising earnings, while SKY's short surge and weak outlook land it as Bear of the Day.
Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors
Berberian brings significant technology leadership and cybersecurity expertise Berberian brings significant technology leadership and cybersecurity expertise ...
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics DGX has outperformed the market over the past 5 years by 304.48% on an annualized basis producing an average annual return of 318.82%. Currently, Quest Diagnostics has a market capitalization of $19.42 billion.
